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Abstract Although popular, the pressurized metered dose inhaler generates coarse, fast moving clouds so that the 
fraction reaching the lung is small. These shortcomings can be redressed by Nodulite ® which permutes the following 
variables: the non-volatile components of a solution formula, the actuator orifice geometry, the volume of the metered 
solution and the vapour pressure of the propellants.This permits the design of aerosols with chosen particle size and plume 
speed.This facilitates co-ordination of dose generation with inspiration, reduces oropharyngeal deposition and provides a 
mechanism for targeting drug delivery to different parts of the lung.These pnndples are exemplified by designing an HFA- 
propelled beclometasone dipropionate product which closely matches existing products which use chlorofluorocarbons. 
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INTRODUCTION 
For almost 50 years the use of pressurized metered dose 
inhalers (pMDIs) has been enormously successful in the 
treatment of asthma and obstructive airways disease. 
However, success has been derived far more from 
forgiving therapeutic indices of drugs such as salbutamol 
and patient preferences than from the intrinsic properties 
of the dosage form. As a delivery vehicle it is far less 
precise than other dosage forms.The dose is generated at 
a high speed, typically 30 m sec -r, over a very short 
period, typically 200 msec.This creates serious problems 
for patients in co-ordinating dose generation with an 
appropriate inspiration and most of the drug impacts in 
the throat and is swallowed.Although these problems can 
be eased by the use of spacers, the dose given becomes 
even more variable depending on the pattern of use. 
The banning of the environmentally damaging chloro- 
fluorocarbons (CFCs) is denying the pharmaceutical 
industry the propellants used hitherto.This has created 
serious problems because the newly approved hydro- 
fluoroalkane propellants, HFA 134a and HFA 227, have 
very different properties that their predecessors which 
complicate product replacement. However, the situation 
does offer an opportunity to re-examine the pMDI, 
retaining its strengths and eliminating its weakness.The 
Modulite ® technology achieves this objective. 
THE EFF IC IENT DEL IVERY OF 
DRUGS TO THE LUNG 
To deliver drugs optimally to the lung requires close 
integration of the device used, the formulation it contains 
and the inspiratory manoeuvre made by the patient.The 
objective is the formation of a slow moving cloud 
containing particles of the required particle size. It 
should be generated over a relatively long period of time 
which permits co-ordination with a slow inspiration by 
the patient. Modulite ® achieves these objectives primarily 
by permuting the two interdependent variables: the 
addition of a non-volatile component to the formulation 
and the geometry of the actuator orifice. Two minor 
variables, change in vapour pressure by mixing available 
propellants and the volume of the metering valve, are 
also used to refine performance. 
THE USE OF NON-VOLAT ILE  
COMPONENTS 
The primary determinant of capture in the lung is the 
aerodynamic size of a particle. This characterizes the 
particle's inertial behaviour - i.e. its ability to cross 
streamlines when entrained in an airstream and its rate 
of sedimentation in a gravitational field. It is largely 
defined by the density and diameter of the particle. 
Although the former is exploited in some specialized 
formulae using porous particles, the size of simpler solid 
particles is the main variable used by the formulator. 
Since particles vary about some average value, it is 
usually expressed as a mass median aerodynamic 
diameter (MMAD) and values of I to 5 ~tm are generally 
accepted as suitable for pulmonary delivery. Particles at 
the high end of this range would deposit centrally in the 
larger conducting airways whereas very fine particle 
would reach the lung periphery. In many formulations, 
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the fraction of the cloud in this size range is quite small 
and is commonly expressed as the fine particle dose 
(FPD) i.e. the fraction of the label claim < 5 JJm. 
Existing CFC products invariably contain solid particles 
milled to a fine size and include them as a suspension in 
the propellant. Milling is a poorly controlled process 
dominated by the physical properties of the drug crystals, 
such as hardness and lattice flaws. Since the resultant size 
dominates the characteristics of the cloud produced by 
the formulation, the latter cannot be optimized. 
An alternative, used in the Modulite ® technology, is to 
dissolve the drug in the propellant with the aid of a co- 
solvent such as ethanol.This brings important advantages 
in performance consistency. Phase separation occurs 
naturally in suspension formulas and variation in shaking 
and storage in the hands of patient can affect dose 
uniformity and the size distribution of the dose. The 
spray content and pattern from solution formulations is 
much more consistent. More importantly, since the spray 
pattern is determined largely by the vapour pressure of 
the propellant, the proportion of co-solvent and the 
dimensions of the actuator orifice, it can be controlled. 
The final particle size distribution then depends on the 
drug concentration in a droplet and any other non- 
volatile components which have been added. The 
permutation of these factors allows the design of a 
product with a chosen particle size distribution. 
With a simple solution, each droplet will dry to give a 
particle, the size of which depends on the concentration 
of the drug in the solution, in practice, the MMAD of 
such formulations is very small with typical values of 
0"8-1"2 ~m. This is the lower end of the useful range, 
yielding a product targeted largely to the alveoli. To 
deliver drug to other chosen regions, a systematic means 
of making somewhat coarser particles is necessary.With 
Modulite ® a non-volatile component, chosen to give no 
pulmonary hazard, is included at the level which gives the 
required enhancement of size. Such changes in cloud size 
may be explained simply in terms of the volumetric 
contribution of the non-volatile component. Assuming 
that the cloud particles approximate to a spherical 
geometry, the size, d, is related to volume, V, by the 
equation: 
d = (6V/~) °33 [I] 
Assuming that atomization patterns are unchanged, 
this size may be increased from a baseline value of d o to 
d t by increasing the volume of the non-volatile 
components from V 0 to V I so that: 
d, = do(VilVo) °33 [2] 
For a given combination of drug, non-volatile excipient 
and propellant and assuming that the spray pattern is 
maintained and density changes are small as the 
composition varies, the diameters in equation 2 can be 
replaced by MMAD to give: 
MMAD I = MMAD 0 (ml/mo) °33 [3] 
where m 0 is the mass of drug in the simple formula of 
drug, co-solvent and propellant and m I is the mass of 
drug plus non-volatile additive. 
The experimental data from Table 1 are plotted in 
Figure I. It shows that simple formulas containing a dose 
of beclometasone dipropionate (BDP) of 50pg or 
250 ~g have an MMAD of 1" I and 1"8 pm, respectively. 
The MMAD can be increased with non-volatile 
additives and, for example, the inclusion of 6% of a 
polyethylene glycol gave an average value of 4-25 IJm. 
These experimental data are plotted in Figure 2 against 
the theoretical dimensions derived from equation 3 and 
close agreement is observed. 
THE EFFECT OF ACTUATOR ORIF ICE  
The effect of actuator geometry on cloud formation has 
been known since the early work of Polli et al. (I) who 
showed that a larger orifice produced a coarser spray. 
However, exploitation of this phenomenon has been 
limited by the use of suspensions which clog finer 
apertures below, say, 0"3 ram. The solution technology 
used in Modulite ® frees the formulation from this 
constraint so that variation in aperture diameter and 
length can be permuted with other variables in designing 
products to a given specification. More importantly, the 
use of fine orifices generates slow moving clouds over a 
much longer period. This reduces oropharyngeal 
deposition and greatly facilitates the co-ordination of 
cloud generation with the inspiration of the patient, 
overcoming a serious problem commonly encountered 
with existing pMDIs. 
Figure 3 describes the changes in the cloud 
characteristics generated from a formula containing 
0-424% w/w BDR I-3% w/w glycerol and 15% w/w 
ethanol in HFA when the actuator orifice diameter is 
varied from 0" 14 to 0-42 mm. 
This has profound changes on the fraction of the spray 
which evaporates to form respirable particles. In the in 
vitro model used for assessment, the output from an 
inhaler is led through a right-angled throat to simulate 
losses in the oro-pharynx before entry into an impactor 
which measures aerodynamic particle size. Use of fine 
orifices massively reduces these losses so that a larger 
fraction of the delivered dose is presented as a fine 
particle dose less than 5/Jm. MMAD of this fraction 
becomes only slightly finer, decreasing from 2"9 ~m to 
2-5 ~m over the range studied.This is explained by the 
data given in Table 2 which shows the MMAD generated 
by the different actuators and the variation in size 
around this mean expressed as a geometric standard 
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Table I. Effect of non-volatile components on BDP-HFA 134a solution pMDI characteristics: mean _+ SD (n > 3) 
Formulation (% w/w) 
BDP 0"085 a 0-424 b 042@ 0"424 b 0-42@ 
Ethanol 14-0 15-0 15-0 5°0 15 "0 
Glycerol 1.0 t -6 
PEG 400 6-I 
HFA 134a 85-9 84-6 83-6 83.0 78"5 
Delivered dose (tag) 43.2 + 1.9 222 ° 1 + 5 ° I 227"9 z 3-6 230"7,232"6 223-4, 228-0 
Fine particle dose (~tg) 14-7 _+ 0-7 65-9 + 4-2 51-8 _~ "6 45'7.46,7 27.5, 28'6 
MMAD @m) I" I + 0. I 1.8 + 0"2 2°9 z 0-3 3-I. 3" I 4"4, 4-1 
GSD 2"2 _+ 0' I 2"2 + 0" I 2"3 7- 0-2 2-3 2-3 2.5, 2.5 
Replicates 6 6 4 2 2 
Actuator orifice 0-33 mm; Metered dose: a50 tag, b250 tag 
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FIGURE I. Effect of total non volatile component on MMAD (tam) of BDP pMDI solution formulations in HFA 134a Data derived 
from Table I 
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FIGURE 2. Relationship between experimental and theoretical MMAD values using Equation 3 and experimental data from Table I 
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FIGURE 3. Effect of actuator orifice on the ~I~IAD and fine particle dose from a BDP formulation containing I 3%w/w glycerol and 
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Table 2. Effect of actuator orifice diameter on the particle size generated by a BDP 250 t~g formula containing 1.3%w/w 
glycerol and ]5%w/w ethanol: mean (_+ SD) 
Diameter Delivered dose Fine particle dose iV]HAD GSD Replicates 
(ram) (~g) (~g) (~m) 
0-14 235'2 + 2'7 194'6 __+ I I-3 2"5 __+ 0-t 
0-22 220"8 __+ 6"0 93"5 __+ 7' I 2"6 __+ O-I 
0-30 " 231"4 __+ 16"0 55"3 __ 1'8 2"7 -I- 0"2 
0"33 228"7 ± 5"3 50'9 ± 1'4 2"9 ± 0"2 
0.42 216"2 __+ 1I'3 34"9 __+ 1"9 2-9 __+ 0-3 
I-7+_0" 
2 -0+0-  
2 -2+0"  
2"2+_0- 
2-3 + 0-2 
5 
3 
+6 
I2 
3 
deviation.With the larger orifices, more coarse particles 
are formed which broadens the distribution and moves 
its mean to higher values. 
Actuator orifice size has a greater influence on plume 
maximum velocity and duration. Over the range studied, 
the maximum velocity of the plume measured at a 
distance of 4 cm from its origin decreased from 
7.15 m sec-I with the largest orifice to 5' 12 m sec-I for 
the smallest. Correspondingly, the plume duration 
increased from 0-18 sec to l-16 sec (Figure 4). 
The use of smaller apertures producing slower clouds 
over a longer period should facilitate the co-ordination 
of cloud generation and the patient's inspiration. 
THE EFFECT OF METEREDVOLUME 
AND PROPELLANT VAPOUR 
PRESSURE 
Although the effect of metered volume and choice of 
propellant is less pronounced, useful modulating effects 
can be obtained.Valves commonly meter volumes from 
25 to 100 pl allowing a degree of freedom in the amount 
of drug and non-volatile component which can be 
delivered. 
HFA 134a and HFA 227 differ significantly in vapour 
pressure; 570 and 390 kPa at 20 ° respectively.Addition of 
co-solvent and non-volati le additive lowers the 
propellant vapour and pack pressures, although those for 
HFA 134a systems remain higher than for equivalent 
HFA 227 systems. Brambilla et aL (2) showed that a 
BDP/ethanol/glycerol combination in a high pack 
pressure HFA 134a formulation (550 kPa at 20 °) gave a 
cloud with an MMAD of 2"8/am compared with 3"5 pm 
when HFA 227 is used (pack pressure at 20 ° = 350 kPa). 
Similar effects were obtained with formulations 
containing budesonide and ipratropium bromide. In all 
cases, higher pressures lead to more efficient 
atomization and finer sprays. However, unlike the effect 
of actuator orifice, there was little associated change in 
fine particle dose. 
THE FORMULATION OF BDP 
US ING HFA 
Although the principles of Modul ite ® permit the 
development of highly efficient formulations to target 
particular parts of the lungs, an immediate opportunity 
arises with the replacement of CFC with HFA in existing 
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FIGURE 4. Effect of actuator orifice on the plume maximum velocity and plume duration for a formulation containing 1"3% w/w 
glycerol and 15% w/w ethanol. 
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FIGURE 5. Phase diagram for BDP (250 Bg/50 ~1) and (1'3 +_ 0'1)% w/w glycerol system, demonstrating the miscibility of BDP, HFA 
134a, absolute ethanol, and water  (T = 0-20°C).  
formulations. Generally, the CFC formulations are far Nevertheless, they are widely used with well-established 
from optimum and in many cases very inefficient, dose regimens. Replacement poses a dilemma. 
depositing only a tiny fraction at the site of action. Modulite®could be used to make a highly efficient 
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FIGURE 6. Comparative in-vitro particle size distribution for three BDP 50Bg piVlDIs: Becotide ® CFC suspension, Modulite ® HFA 
solution, and Qvar e HFA solution, 
product. However, when Leach et al. (3) devised the 
QVAR ® solution formulation of BDP with a much reduced 
MMAD of I'1 gm, the effective dose was more than 
halved and a complex dose conversion was required (4). 
The alternative is to use Modulite ® to match the 
properties of existing products, maintaining established 
dose schedules and promoting a seamless transition. 
In using Modulite ® to match existing products, solubility 
studies to establish likely formulations containing BDR the 
chosen HFA, ethanol and small amounts of water were 
first performed. Formulations were assessed visually in 
special glass containers and a phase diagram created 
which displays the regions in which combinations of HFA 
134a, ethanol and water will dissolve 0.424% w/w BDP to 
give a single phase (Figure 5). 
Water was added to establish the tolerance of the 
formulations to ingress which arises from absorption 
during processing and storage. 
This data was allied to the inclusion of non-volatile 
components and the selection of aperture orifices, 
assessed using the in-vitro model described above and 
exemplified in Tables I and 2. 
Selection was made by permuting variables to give the 
closest match to the comparator formulation. When a 
formulation containing 0-085% w/w BDP, 1.3% w/w 
glycerol and 13% w/w ethanol in HFA134a was equipped 
with a Bespak BK357 valve, the particle size distribution 
given in Figure 6 was obtained. 
Data for a comparator CFC suspension formula 
(Becotide ® 50, Allen and Hanbury) and a simple solution 
formula (Qvar ® 50, 3M) are also given. It is immediately 
apparent that Qvar ® produces a very fine particle cloud 
with large amounts of the dose as particles less than 
2 gm. The match between Modulite ® and Becotide ® is 
very much closer. It is not, however, perfect because the 
physical mechanisms in the atomisation of suspensions 
and solutions will differ. However, in the therapeutically 
useful range I. I-4.7 ~m, the Modulite ® formulation gives a 
value of I 1-6 ~g compared with 10"3 ~g for Becotide®.The 
HFA formulation has marginally more fine particles below 
I ~m, depressing the MMAD from Becotide®'s 3"4 gm to 
2-9 gm. Nevertheless, physical characteristics are such that 
a product close to being pharmaceutically equivalent can 
be claimed. Differences in clinical performance are, 
therefore, unlikely and simple substitution can be made 
without change of dose or regimen. 
CONCLUSIONS 
The principles of Modulite ® permute two major 
variables - the non-volatile content of a solution formula 
and the actuator orifice geometry - and two minor 
variables - metered volume and vapour pressure of the 
propellant - to design aerosols with chosen particle size 
and plume speed. This facilitates co-ordination of dose 
generation with inspiration and provides a mechanism 
for targeting drug delivery to different parts of the lung. 
The principles are powerfully exemplified by designing a 
HFA-propelled beclometasone dipropionate product 
which closely matches an existing product which uses 
chlorofiuorocarbons. 
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